What happened Cordis?
Table of Contents
What happened Cordis?
Cardinal Health acquired Cordis from Johnson & Johnson in 2015 for $2 billion. Cardinal Health said it was selling its Cordis cardiovascular business to private equity firm Hellman and Friedman for $1 billion. The transaction is expected to close in the first half of Cardinal Health’s fiscal year 2022.
Who bought Cordis from Cardinal Health?
Hellman & Friedman
Cardinal Health completes sale of Cordis business to Hellman & Friedman. DUBLIN, Ohio, Aug. 2, 2021 /PRNewswire/ — Cardinal Health (NYSE: CAH) and Hellman & Friedman (H&F) announced today the completion of the previously announced sale of Cardinal Health’s Cordis business to H&F.
What company bought Cordis?
DUBLIN, Ohio, March 12, 2021 /PRNewswire/ — Cardinal Health (NYSE: CAH) today announced that it has signed a definitive agreement to sell its Cordis business to Hellman & Friedman (H&F) for approximately $1 billion, which includes buyer’s assumption of certain liabilities and seller’s retention of certain working …
Is Cordis a public company?
Medical supplies and drugs distributor Cardinal Health on Friday announced it has signed a definitive agreement to sell its Cordis business to private equity firm Hellman & Friedman for approximately $1 billion.
Is Cordis a private company?
Who is the CEO of Cordis?
CEO Shar Matin
CEO Shar Matin is ushering in a bold new era for Cordis, grounded in 20-plus years of medical device experience in Fortune 500 and mid/small cap companies where he led commercial and technical teams in the United States, Europe and Asia.
Is Cordis public?
CORDIS has a rich and structured public repository with all project information held by the European Commission such as project factsheets, participants, reports, deliverables and links to open-access publications.
What type of company is Cordis?
Cordis is an independent, customer-focused provider of interventional cardiovascular technologies. During our 60-year history we’ve established a legacy of pioneering breakthrough technologies, including the first guiding catheters and coronary drug eluting stents.
